Key insights
- Rocket Lab's stock is up following Germany's approval of its Mynaric acquisition, securing optical communication tech for its $1.3B Space Development Agency contract. Analyst Erik Rasmussen reiterated a Buy rating with a $90 target. Positive sentiment around the space industry, potentially fueled by a SpaceX IPO, also contributes. Rocket Lab's $1.85B contracted backlog, up 73% year-over-year, further supports a bullish outlook.

The primary catalyst for Rocket Lab’s stock strength today was continued positive sentiment following Germany’s Federal Ministry for Economic Affairs and Energy’s approval to acquire Mynaric, with Mynaric remaining headquartered in Munich and creating Rocket Lab’s first European footprint. The acquisition brings laser optical communications terminals in-house and supports Rocket Lab’s role on a $1.3 billion Space Development Agency prime contract to produce 36 satellites. In addition, positive sentiment around the space industry tied to SpaceX’s upcoming IPO is helping the sector.
For Rocket Lab, bringing Mynaric in-house resolves a meaningful supply chain dependency. The company holds two contracts with the U.S. Space Development Agency with a combined value of approximately $1.3 billion, both of which require the kind of optical terminal technology Mynaric produces. Sourcing that component from an external vendor introduces scheduling and cost variables that Rocket Lab would rather control directly. Absorbing Mynaric’s manufacturing and engineering capabilities gives the company that control.
Following the announcement, Stifel analyst Erik Rasmussen reiterated his buy rating and $90 price target, maintaining Buy with a $90 target. Rasmussen, ranked #137 out of over 12,000 analysts tracked on TipRanks, has a 72% success rate and an average return of 36.10% per rating. Clear Street recently initiated coverage with a buy rating, citing the company’s vertically integrated model and the long-term growth potential of its Neutron and Electron launch vehicle programs, though the acquisition also gives Rocket Lab something it did not previously have: a physical operational presence in Europe.
Supporting the bullish thesis, Rocket Lab ended 2025 with a $1.85 billion contracted backlog up 73% year-over-year, including an $816 million Space Development Agency contract for 18 satellites and a $190 million Department of War contract for 20 hypersonic test flights. Non-GAAP gross margin expanded 10 points to 44.3% in Q4 2025 with full-year gross profit growing 78% versus 38% revenue growth. RKLB reported its most recent earnings on February 26, 2026 for Q4 2025, posting earnings per share (EPS) of -$0.09, which exceeded analysts’ expectations of -$0.09 by 0.00%, marking a Meet.
The broader market context proved favorable today, with the S&P 500 up 0.69% or by 45 points as the main stock market index of United States, the US500, rose to 6574 points on April 1, 2026, gaining 0.70% from the previous session. All on hopes the war with Iran will soon end. According to President Trump, the war could be over in two to three weeks. US equity indices were higher for a second session on Wednesday after President Trump threatened to escalate the war should Iran continue to target vessels in the Strait of Hormuz. Tech giants rose as stronger risk sentiment coincided with bullish signs for the AI sector following OpenAI’s fresh funding round, with new backing by Nvidia, Amazon, and SoftBank.
The combination of transformative M&A progress, a massive contracted backlog exceeding $1.85 billion, improving operational margins, and a supportive macroeconomic backdrop created ideal conditions for Rocket Lab’s stock to extend its recent gains today. The Mynaric acquisition not only secures critical supply chain components for over $1 billion in existing contracts but also opens the door to European Space Agency programs that were previously inaccessible, positioning the company for sustained long-term growth in both commercial and defense markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.